This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Xydalba
  • /
  • Single Dose vs. Two Dose Regimen of Dalbavancin fo...
Clinical trial

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Read time: 1 mins
Last updated:1st Apr 2014

To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in patients with known or suspected Gram-positive abSSSI (acute bacterial skin and skin structure infections) at 48 -72 hours after initiation of treatment.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Enrollment: 698
Study Start Date: April 2014
Study Completion Date: March 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Single Dose Dalbavancin
- Experimental: Two Dose Dalbavancin

Category Value
Study start date 2014-04-01

View full details